Remedium Capital Partners, LLC holds a concentrated book of 6 stocks worth $281.2M as of Q1 2026 (disclosed May 19, 2026, a ~45-day 13F lag). Their largest long position is Oruka Therapeutics Inc at 27% of the equity book. Cloning the disclosed picks since 2026 would be +125% (+506.1%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2104501/holdings"
Use Arkolith to show Remedium Capital Partners, LLC's latest holdings, largest changes, and filing provenance.
Following at the filing date actually beat the quarter-end book by 18.5 points over this window.
Growth of $10,000 cloning Remedium Capital Partners, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
No trims or exits this quarter.
Other tracked managers holding the same core names as Remedium Capital Partners, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| FMR LLC | 5 / 6 | $2.1B |
| Venrock Adviser, LLC | 5 / 6 | $1.2B |
| BlackRock, Inc. | 5 / 6 | $833.7M |
| Fairmount Funds Management LLC | 5 / 6 | $699.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5 / 6 | $486.5M |
| VANGUARD GROUP INC | 5 / 6 | $455.0M |
| STATE STREET CORP | 5 / 6 | $406.7M |
| JANUS HENDERSON GROUP PLC | 5 / 6 | $388.0M |
Ranked by how many of Remedium Capital Partners, LLC's top 6 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Oruka Therapeutics Inc COM | $76.8M | 1.57M | 27.3% | ▲+0.8% Added · +13K sh | |
| 2 | Spyre Therapeutics Inc COM | $73.5M | 1.46M | 26.1% | —Held | |
| 3 | Damora Therapeutics Inc COM | $53.0M | 2.05M | 18.8% | ▲17× Added · +1.9M sh | |
| 4 | Apogee Therapeutics Inc COM | $49.1M | 583.6K | 17.5% | —Held | |
| 5 | Jade Biosciences Inc COM | $22.2M | 1.58M | 7.9% | —Held | |
| 6 | Crescent Biopharma Inc COM | $6.6M | 361.3K | 2.4% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 19, 2026 | 6 | $281.2M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 6 | $170.2M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.